Log In
Print
BCIQ
Print
Print this Print this
 

Asacol, mesalamine

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionDelayed-release formulation of mesalamine (5-aminosalicylic acid)
Molecular Target Not available
Mechanism of ActionUndisclosed
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat mildly to moderately active ulcerative colitis (UC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,100.0M

$3,100.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today